In volume five, of the eighth issue on Aging Journal, Mikhail Blagosklonny discuses about TOR Signaling in aging. According to Mikhail, aging is “an exponential increase of the probability of death with age.” Elderly people die from age-related diseases. Some of these diseases include cardiovascular diseases, cancer, diabetes, Parkinson diseases, Alzheimer and muscular degeneration. Cellular aging, which is partly dependent on MTOR, is activated by growth factors such as hormones, oxygen, nutrients, and conditions like obesity. Conversely, MTOR initiates specific functions of differentiated cells and mass growth of cells.
Aging is also connected to systematic hyper-functions like hypertension, hyper-aggregation, hyper-contractility of arterial smooth muscle cells, as well as hyperplasia, hyperinsulinemia, pro-inflammatory conditions and fibroids among others. These hyper-functions damage body organs. Terminal stages of these hyper-functions cannot be revived with rapamycin since they are MTOR-independent. Rapamycin is an MTOR inhibitor and a common cancer drug. Mikhail proposes that the drug should be used for life extension. Rapamycin is a stronger inhibitor of MTOR compared to calorie restriction. Mikhail found out that Rapamycin extended lifespan in all tested species. MTOR is related to aging-related diseases. The study also revealed that genetic manipulations, which inhibit TOR’s pathway, elongate lifespan in many species, including yeast and mammals. Read more on Impact Journals.
About Mikhail Blagosklonny
Mikhail Blagosklonny is a renowned cancer and aging scientist, He serves as an oncology professor at Roswell Park Cancer Institute. Mikhail is known for his in-depth research on cancer and aging where he formulated a hypothesis to find out the possible role of Rapamycin in extending the life of people living with cancer. His deep involvement in the field has seen him become the most passionate advocate for rapamycin drug in longevity research. Mikhail was admitted to First Pavlov State Medical University, St. Petersburg, where he received his M.D. in internal medicine and a PhD in experimental medicine and cardiology. Mikhail has worked for New York Medicine College as an associate professor. For nine years, he served as a senior scientist at the Ordway Research Institute. Mikhail is the Editor-in-Chief of various journals, including Aging, Oncotarget, and Cell Cycle. He is also an associate editor for a journal known as Cancer Biology & Therapy. View Mikhail’s profile in LinkedIn